Infinity Pharmaceuticals Inc. logo

INFI

Infinity Pharmaceuticals Inc. · NASDAQ

Website

Infinity Pharmaceuticals Inc. (INFI) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for INFI in the last 30 days. The most recent was published Sep 29, 2023.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.

Latest news

25 items

INFI FAQ

7 questions
  • What does Infinity Pharmaceuticals Inc. do?
    Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem...
  • What is the latest news on INFI?
    Quantisnow has not tracked any new filings, ratings or press releases for INFI in the last 30 days. The most recent wire item was published on September 29, 2023.
  • Where does INFI stock trade?
    Infinity Pharmaceuticals Inc. (INFI) is listed on NASDAQ.
  • What sector and industry is INFI in?
    Infinity Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • What are analysts saying about INFI?
    Across the last 4 analyst actions on Infinity Pharmaceuticals Inc., there were 2 upgrades and 0 downgrades. The most recent action was from HC Wainwright & Co.: Buy with a $9.00 price target on 2021-10-18. Recent price targets range from $6.00 to $14.00.
  • What companies are similar to INFI?
    Notable peers in the same industry include ABT (Abbott Laboratories), JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC). Compare INFI side-by-side with any of them on Quantisnow.
  • How can I track INFI on Quantisnow?
    Quantisnow aggregates Infinity Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INFI to receive live email and push alerts on every new disclosure.